Insights Archive
Filter by:
April 3, 2024
Rezdiffra (resmetirom)
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.
April 3, 2024
Understanding Biosimilar Basics
With Humira® biosimilars expected to have a significant impact in 2024, some ClearScript clients are asking for more information. Here we provide the biosimilar basics and what their increasing presence in the marketplace means to the pharmacy benefit.
January 11, 2024
Navigating 2024: Three topics shaping the pharmacy benefit
As we reflect on the developments of 2023 and set our sights on 2024, the pharmacy benefit landscape is undergoing significant transformations. Read on to learn what ClearScript is watching in this evolving and complex field to stay ahead of changes that will impact the pharmacy benefit.
September 29, 2023
Insulin Update
Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?
May 30, 2023
Weight loss drugs and pharmacy benefit coverage
As more people are lured to these medications with hopes of an effective weight loss solution, many plan sponsors are growing concerned about their impact on plan spend.